



Full Length Research Article

Advancements in Life Sciences – International Quarterly Journal of Biological Sciences

ARTICLE INFO

Open Access



Date Received:
21/11/2021;
Date Revised:
12/11/2022;
Date Published Online:
31/03/2023;
Date Updated:
05/09/2025

In Silico Analysis of Differentially Expressed Genes in Colorectal Carcinoma

Sobia Hassan^{1*}, Talat Mirza², Ambrina Khatoon², Uzma Bukhari³, Fouzia Shaikh¹

Abstract

Background: Colorectal carcinoma (CRC) is a primary cause of morbidity and mortality worldwide. Resistance to therapy contributes to poor patient prognosis. This study aimed to identify key proteins and interaction networks implicated in CRC that may serve as therapeutic targets and help overcome therapy resistance.

Methods: We analyzed a microarray dataset comprising 58 CRC cases and 62 controls (total n = 120) to identify differentially expressed genes (DEGs). Protein-protein interaction (PPI) networks were constructed, and Cytoscape analysis was performed to identify the hub proteins. Based on subgraph centrality, betweenness and degree (≥ 10), hub proteins were selected for further literature search and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis.

Results: A total of 95 up-regulated genes and 85 down-regulated genes of CRC patients were selected based on criteria of $P < 0.05$ and fold change > 2.0 . The PPI analysis revealed *STAT3*, *HNRNPA2B1*, *RBM8A*, *RBM25*, *ATM*, *HIST1H2BK*, *SRSF5* and *HNRNPDL* as hub proteins. Based on criteria set for Cytoscape analysis, *STAT3* and *HNRNPA2B1* were identified as key hub proteins. KEGG pathway analysis revealed vital role of *STAT3* in carcinogenesis.

Conclusion: In addition of *HNRNPA2B1* activation by *STAT3*, crosstalk of *STAT3* with other oncogenic signaling pathways signifies its role in colorectal carcinogenesis. Our study highlights that *STAT3* may be a possible therapeutic target which may help in overcoming the dilemma of resistance to drug treatment in advanced cases.

Authors' Affiliation:

1. Department of Pathology, Ziauddin Medical University, Karachi - Pakistan
2. Research Department, Ziauddin Medical University Karachi - Pakistan
3. Department of Pathology, Dow University of Health Sciences Karachi - Pakistan

*Corresponding Author:

Dr. Sobia Hassan
Email:
sobia10722@zu.edu.pk

How to Cite:

Hassan S, Mirza T, Khatoon A, Bukhari U, Shaikh F (2023). In Silico Analysis of Differentially Expressed Genes in Colorectal Carcinoma. Adv. Life Sci. 10(1): 37-41.

Keywords:

STAT3; Drug resistance; Targeted therapy; Bioinformatics

Editorial Note:

You are viewing latest version of this article having language corrections.



Introduction

CRC denotes a primary cause of morbidity and mortality worldwide [1]. The World Health organization (WHO) data reports that out of 9.6 million cancer related deaths that occur globally, colorectal carcinoma (CRC) results in approximately 0.862 million deaths [2]. Bailey et al in 2015 documented that CRC risk will show an increase of about 90% in a decade [3,4]. Although CRC is curable if diagnosed early, it remains the second most common cause of cancer-related mortality [4]. The advancement of treatment modalities has achieved only a slight improvement in survival rate [5]. Mainstay of CRC treatment is surgery. If surgery fails to offer complete remission, target-based therapy, neoadjuvant radiotherapy and adjuvant chemotherapy is indicated. However, drug resistance remains one of the vital reasons for poor overall survival rate of CRC patients [5]. Patients experience treatment resistance and relapse of disease which may be attributed to plethora of molecular events defining complex pathogenesis of CRC [6,7]. Understanding of molecular events responsible for therapy resistance can open avenues for drug development and improved patient management [8].

It is imperative to explore possible molecular targets of colon cancer and to determine the molecular mechanisms associated with drug resistance. This will support the designing of novel strategies for successful treatment of patients with CRC [9,10]. Bioinformatics tools have gained popularity due to their use in collection, classification and analysis of biological datasets including the gene expression microarray datasets. The world has stepped towards precision medicine based on bioinformatics analysis for identifying the dynamic molecular events that determine disease pathogenesis [11]. Data mining of the available microarray datasets may act as a key source for understanding the molecular pathogenesis and for carrying out targeted experiments. Deeper understanding of genetic alterations in colorectal carcinoma and the functional consequences of these mutations can lead to improved therapeutic approach and better patient management.

Methods

Ethical consideration: The study has been carried out after approval from Ethics Review Committee of Ziauddin University (2861120SHPAT). The study was conducted in the Multidisciplinary Laboratory, Ziauddin University. (See Figure 1 for the workflow). In our study the microarray dataset was obtained from Gene Expression Omnibus (GEO) database (<http://www.ncbi.nlm.nih.gov/geo/>).




Figure 1: Selection criteria and workflow of the Study. After selection of DEGs, protein-protein interaction was studied using STRING which led to identification of hub genes. Literature search and KEGG analysis of key hub genes was carried out.

Identification of DEGs: We analyzed a microarray dataset (GSE164191) comprising 58 CRC cases and 62 controls (total n = 120), obtained from the NCBI Gene Expression Omnibus (GEO). The identification of DEGs was done based upon p value to test the differential expression of the genes between the CRC and the control groups. The p value was calculated using the student's t-test. The cut-off criteria were kept at the fold change > 2.0 and a corrected p < 0.05.

PPI analysis: To perform the PPI analysis, online database Search Tool for the Retrieval of Interacting Genes was used. The parameter of interactions was set as confidence > 0.4. To visualize and analyze the PPI network, Cytoscape software was used. The scattered proteins in cytoscape were removed from the final PPIs. Proteins functioning as hubs in the network were selected by CytoNCA based on their interaction with other proteins. The selection was based upon degree centrality, between-ness centrality and sub graph centrality. The degree was set at ≥ 10 for further selection of hub proteins.

Literature search: Manual literature search was performed to explore the role of the selected hub proteins in CRC.

KEGG Pathway analysis: The selected hub proteins were searched for associated pathways in human cancers using KEGG pathway analysis.

Results

DEGs: There were 95 up-regulated genes and 85 down-regulated genes among the total of 180 DEGs which were selected according to the defined criteria (Figure 2; Supplementary Dataset S1).




Figure 2: Volcano plot GSE 164191: Highlighted genes are significantly differentially expressed in blood-based analysis of colorectal cancer and healthy controls.

PPI network Analysis: After initial input of 180 selected DEGs, 148 DEGs with mean confidence score >0.4 were used to construct PPI (Figure 3). Identification of genes which were closely related to others was done using degree centrality, between-ness centrality and sub graph centrality, and selected at degree ≥ 10 (Table1). This analysis highlighted *STAT3*, *HNRNPA2B1*, *RBM8A*, *RBM25*, *ATM*, *HIST1H2BK*, *SRSF5* and *HNRNPDL* as key differentially expressed proteins.




Figure 3: Protein-Protein Interaction network constructed with DEGs. The nodes represents proteins while the edges represent the protein-protein associations.

Selection of hub genes: A manual literature search was done on the top hub genes, *STAT3* and *HNRNPA2B1* to identify their role in CRC. Based on the results of CytoNCA analysis and literature search, *STAT3* was chosen as hub protein. Literature showed a significant role of *STAT3* in colorectal carcinogenesis as well as in associated therapy resistance.

Degree	Sub graph	Betweenness
STAT3	HNRNPA2B1	STAT3
RBM25	SRSF5	RBM8A
HNRNPA2B1	RBM25	ATM
ATM	HNRNPDL	HIST1H2BK

Table 1: Hub proteins identified by Cytoscape analysis
STAT3 Signal Transducer and Activator of Transcription 3; *HNRNPA2B1* Heterogeneous nuclear ribonucleoprotein A2/B1; *RBM* RNA Binding Motif Protein (*RBM25*; *RBM8A*); *SRSF5*: Serine/Arginine-rich slicing Factor 5; *ATM* Ataxia-Telangiectasia and Mantle Cell Lymphoma; *HIST1H2BK*: Histone Cluster 1 H2B Family Member *HNRNPDL*: Heterogeneous Nuclear Ribonucleoprotein D Like

KEGG pathway analysis: KEGG pathway analysis of *STAT3* in human cancers (map05200) revealed pathways associated with *STAT3* including cytokine receptor interactions, MAP kinase signaling pathway, *PI3K/AKT* signaling pathway and *JAK/STAT* pathway (Fig 4). KEGG pathway analysis did not reveal significant role of *HNRNPA2B1* in CRC.




Figure 4: KEGG pathway analysis showing association of *STAT3* with several oncogenic pathways. (high resolution image is available in the HTML version of this manuscript).

Discussion

In our study we aimed to find out vital protein interaction networks in colorectal cancer. The comparison of dataset between normal controls and colorectal cancer patients revealed 180 DEGs in which 95 were up regulated and 85 were down-regulated. The DEGs were selected for PPI construction which led to identification of two key proteins, heterogeneous nuclear ribonucleoprotein A2/B1 (*HNRNPA2B1*) and Signal transducer and activator of transcription 3 (*STAT3*) based on sub graph centrality, degree and

betweenness. On exploring literature, we found association of these two proteins with colorectal carcinogenesis. The primary role of *HNRNPA2B1* has been documented in pathogenesis of amyotrophic lateral sclerosis [12,13]. Studies have reported that *HNRNPA2B1* can promote colorectal tumour cell invasiveness [14]. It has been suggested that *HNRNPA2B1* facilitates tumor metastasis through extracellular regulated protein kinases (ERK) pathway [15]. Moreover, the expression and splicing of RAF kinase has been documented to be regulated by *HNRNPA2B1* [16]. Moreover, the heterogeneous nuclear ribonucleoproteins (HNRNPs) have been reported to be associated with *JAK STAT* signaling pathway with up regulation of *HNRNPs* via *STAT3* activation [17,18]. *STAT3* is a member of the STAT protein family, which regulates cell growth and proliferation [19]. Among the family of *STAT* proteins, *STAT3* has been reported to be overexpressed in about 70% cancer [20]. KEGG pathway analysis highlights the association of *STAT3* with human cancers. Activation of *STAT3* may be due to phosphorylation signals by cytokines like IL6, activated Janus kinases (*JAK*), activated epidermal growth factor receptor (*EGFR*) or by mitogen activated pathway (*MAP*) kinases. Activated *STAT3* can lead to increased transcription of target genes including cell-cycle regulator genes, proto-oncogenes, and anti-apoptotic genes. In this era of precision medicine, anti-EGFR drugs have gained popularity with *EGFR* being a possible therapeutic target in CRC patients especially in patients where surgery does not offer complete cure [21]. However, the development of resistance to anti-EGFR targeted therapies has narrowed their scope in CRC therapeutics [21]. Several kinases associated signalling pathways have been implicated as possible mediators of resistance to anti-EGFR targeted therapy [22,23]. Zulkifli et al documented upon the role of *STAT3* signaling in providing tumour cells with an escape mechanism to inhibitory effects of anti-EGFR drugs [23]. Our search of KEGG pathways highlights the association of *STAT3* activation with *EGFR* which indicates that *STAT3* is an important protein contributing to stepwise accumulation of genetic events in colorectal Carcinogenesis. Hence anti-EGFR therapy resistance may be due to downstream activation of *STAT3*. Moreover, the role of *STAT3* in CRC chemotherapy resistance has been studied by *STAT3* inhibition which can sensitize colorectal cancer cells to 5-Fluorouracil (5-FU) therapy through down-regulating cyclinD1 [24]. This resistance may be attributed to *STAT3* activation through cytokine receptor activation. The phosphorylation of cytokine receptors is triggered by Janus kinase which leads to activation of cytokine receptor associated kinases namely *EGFR*, fibroblast growth factor receptor (*FGFR*), platelet-derived growth factor receptor (*PDGFR*), and

receptor-associated kinases that activate *STAT3* [25]. *JAK2* and *STAT3* activation may play a significant role in promoting CRC metastasis [26]. Tsai et al. demonstrated that progression of colon cancer can be attributed to *JAK2* and *STAT3* activation by IL-6 [27]. Furthermore, the negative regulators of *STAT3* like suppressors of cytokine signaling are believed to be perturbed in malignancy [28]. Studies have reported that *STAT3* levels are higher in dedifferentiated colon cells and that there is a negative correlation between high levels of *STAT3* and prognosis of CRC [4].

Clinical trials are ongoing to explore efficacious target therapy based on inhibiting *STAT3*. However *STAT3* inhibitors have not been marketed as yet. Rational bioinformatics tools along with reliable assays are critical for attaining this aim. Because of the crosstalk between *STAT3* and other oncogenic signaling pathways drug repurposing approach for chemotherapy may lead to better cancer management. Furthermore, the development of *STAT3* inhibitors in combination with other therapies may help in formulating effective cancer treatment [29]. Our analysis highlights *STAT3* as the hub gene which is associated with CRC. The association of *STAT3* with CRC related pathways highlights the need of further research on *STAT3* as a possible therapeutic target. This may help in overcoming the treatment failure associated with drug therapy such as anti-EGFR therapy resistance.

Competing Interest

The authors declare that there is no conflict of interest.

Author Contributions

Sobia Hassan : conceptualization ,data acquisition, manuscript writing and editing, correspondence
 Talat Mirza: designing the study, editing, revising and final manuscript approval
 Ambrina Khatoon: data acquisition ,analysis and interpretation, manuscript writing
 Uzma Bukhari: data analysis and interpretation, manuscript writing and editing
 Fouzia Shaikh : manuscript writing and editing.

References

1. Jiang D, Liao J, Duan H, Wu Q, Owen G, et al. A machine learning-based prognostic predictor for stage III colon cancer. *Scientific reports*, (2020); 10(1): 1-9.
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, (2018); 68(6): 394-424.
3. Bailey CE, Hu C-Y, You YN, Bednarski BK, Rodriguez-Bigas MA, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. *JAMA surgery*, (2015); 150(1): 17-22.
4. Chalikhonda G, Lee H, Sheik A, Huh YSJM, Biochemistry C. Targeting key transcriptional factor *STAT3* in colorectal cancer. *Molecular and Cellular Biochemistry*, (2021); 4763219-3228.

5. Xie Y-H, Chen Y-X, Fang J-YJSt, therapy t. Comprehensive review of targeted therapy for colorectal cancer. *Signal transduction and targeted therapy*, (2020); 5(1): 22.
6. Hervieu C, Christou N, Battu S, Mathonnet MJC. The role of cancer stem cells in colorectal cancer: from the basics to novel clinical trials. *Cancers*, (2021); 13(5): 1092.
7. McCuaig S, Barras D, Mann EH, Friedrich M, Bullers SJ, et al. The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon CancerIL22 Pathway and Mutant KRAS Promote Poor Prognosis in Colorectal Cancer. *Clinical Cancer Research*, (2020); 26(16): 4313-4325.
8. Van der Jeught K, Xu H-C, Li Y-J, Lu X-B, Ji GJWjog. Drug resistance and new therapies in colorectal cancer. *World journal of gastroenterology*, (2018); 24(34): 3834.
9. Das PK, Islam F, Lam AKJC. The roles of cancer stem cells and therapy resistance in colorectal carcinoma. *Cells*, (2020); 9(6): 1392.
10. Zhang L, Jiang B, Zhu N, Tao M, Jun Y, et al. Mitotic checkpoint kinase Mps1/TTK predicts prognosis of colon cancer patients and regulates tumor proliferation and differentiation via PKC α /ERK1/2 and PI3K/Akt pathway. *Medical Oncology*, (2020); 37:1-10.
11. Jia L, Fu W, Jia R, Wu L, Li X, et al. Identification of potential key protein interaction networks of BK virus nephropathy in patients receiving kidney transplantation. *Scientific reports* (2018); 8(1): 5017.
12. Fifta JA, Zhang KY, Galper J, Williams KL, McCann EP, et al. Genetic and pathological assessment of hnRNPA1, hnRNPA2/B1, and hnRNPA3 in familial and sporadic amyotrophic lateral sclerosis. *Neurodegenerative Diseases*, (2017); 17(6): 304-312.
13. Xue YC, Ng CS, Xiang P, Liu H, Zhang K, et al. Dysregulation of RNA-binding proteins in amyotrophic lateral sclerosis. *Frontiers in molecular neuroscience*, (2020); 13:78.
14. Zhang Y, Huang W, Yuan Y, Li J, Wu J, et al. Long non-coding RNA H19 promotes colorectal cancer metastasis via binding to hnRNPA2B1. *Journal of Experimental & Clinical Cancer Research*, (2020); 39(1): 1-15.
15. Dai S, Zhang J, Huang S, Lou B, Fang B, et al. HNRNPA2B1 regulates the epithelial-mesenchymal transition in pancreatic cancer cells through the ERK/snail signalling pathway. *Cancer cell international*, (2017); 17(1): 1-13.
16. Hu Y, Sun Z, Deng J, Hu B, Yan W, et al. Splicing factor hnRNPA2B1 contributes to tumorigenic potential of breast cancer cells through STAT3 and ERK1/2 signaling pathway. *Tumor Biology*, (2017); 39(3): 1010428317694318.
17. Li H, Liu J, Shen S, Dai D, Cheng S, et al. Pan-cancer analysis of alternative splicing regulator heterogeneous nuclear ribonucleoproteins (hnRNPs) family and their prognostic potential. *Journal of cellular and molecular medicine*, (2020); 24(19): 11111-11119.
18. Yao A, Xiang Y, Si YR, Fan LJ, Li JP, et al. PKM2 promotes glucose metabolism through a let-7a-5p/Stat3/hnRNP-A1 regulatory feedback loop in breast cancer cells. *Journal of cellular biochemistry*, (2019); 120(4): 6542-6554.
19. Yang Y, Wang G, He J, Ren S, Wu F, et al. Gender differences in colorectal cancer survival: a meta-analysis. *International journal of cancer*, (2017); 141(10): 1942-1949.
20. Wei N, Li J, Fang C, Chang J, Xirou V, et al. Targeting colon cancer with the novel STAT3 inhibitor bruceantinol. *Oncogene*, (2019); 38(10): 1676-1687.
21. Zhuang Y, Bai Y, Hu Y, Guo Y, Xu L, et al. Rhein sensitizes human colorectal cancer cells to EGFR inhibitors by inhibiting STAT3 pathway *OncoTargets and therapy*, (2019); 5281-5291.
22. Jin J, Guo Q, Xie J, Jin D, Zhu YJP, et al. Combination of MEK inhibitor and the JAK2-STAT3 pathway inhibition for the therapy of colon cancer. *Pathology & Oncology Research* (2019); 25769-775.
23. Zulkifli AA, Tan FH, Putoczki TL, Stylli SS, Luwor RBJM, et al. STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics. *Molecular and cellular endocrinology*, (2017); 45115-23.
24. Mohassab AM, Hassan HA, Abdelhamid D, Abdel-Aziz MJPR. STAT3 transcription factor as target for anti-cancer therapy. *Pharmacological Reports*, (2020); 721101-1124.
25. Park S-Y, Lee C-J, Choi J-H, Kim J-H, Kim J-W, et al. The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance. *Journal of Experimental & Clinical Cancer Research*, (2019); 38(1): 1-18.
26. Zhang X, Hu F, Li G, Li G, Yang X, et al. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. *Cell death & disease*, (2018); 9(2): 25.
27. Tsai KS, Yang SH, Lei YP, Tsai CC, Chen HW, et al. Mesenchymal stem cells promote formation of colorectal tumors in mice. *Gastroenterology*, (2011); 141(3): 1046-1056.
28. Wong AL, Hirpara JL, Pervaiz S, Eu J-Q, Sethi G, et al. Do STAT3 inhibitors have potential in the future for cancer therapy? Expert opinion on investigational drugs, (2017); 26(8): 883-887.
29. Dong J, Cheng X-D, Zhang W-D, Qin J-JJJoMC. Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation. *Journal of Medicinal Chemistry*, (2021); 64(13): 8884-8915.



This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 International License. To read the copy of this license please visit: <https://creativecommons.org/licenses/by-nc/4.0/>